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Abstract 
There are no generally accepted protocols for post-mortem assessment in cases of 
suspected vascular cognitive impairment. Neuropathologists from 9 UK centres have 
collaborated in the development of a set of Vascular Cognitive Impairment 
Neuropathology Guidelines (VCING), representing a validated consensus approach to 
the post-mortem assessment and scoring of cerebrovascular disease in relation to 
vascular cognitive impairment. The development had three stages: (i) agreement on a 
sampling protocol and scoring criteria, through a series of Delphi-method surveys; (ii) 
determination of inter-rater reliability for each type of pathology in each region 
sampled (Gwet's AC2 coefficient); (iii) empirical testing and validation of the criteria, 
by blinded post-mortem assessment of brain tissue from 114 individuals (55 to 100 
years) without significant neurodegenerative disease who had had formal cognitive 
assessments within 12 months of death. Fourteen different vessel and parenchymal 
pathologies were assessed in 13 brain regions. Almost perfect agreement (AC2 > 0.8) 
was found when the agreed criteria were used for assessment of leptomeningeal, 
cortical and capillary cerebral amyloid angiopathy, large infarcts, lacunar infarcts, 
microhaemorrhage, larger haemorrhage, fibrinoid necrosis, microaneurysms, 
perivascular space dilation, perivascular haemosiderin leakage, and myelin loss. 
There was more variability (but still reasonably good agreement) in assessment of the 
severity of arteriolosclerosis (0.45 – 0.91) and microinfarcts (0.52 – 0.84). Regression 
analyses were undertaken to identify the best predictors of cognitive impairment. 
Seven pathologies – leptomeningeal cerebral amyloid angiopathy, large infarcts, 
lacunar infarcts, microinfarcts, arteriolosclerosis, perivascular space dilation and 
myelin loss – predicted cognitive impairment. Multivariable logistic regression 
determined the best predictive models of cognitive impairment. The preferred model 
		
included moderate/severe occipital leptomeningeal cerebral amyloid angiopathy, 
moderate/severe arteriolosclerosis in occipital white matter, and at least one large 
infarct (area under the ROC curve 77%). The presence of 0, 1, 2 or 3 of these features 
resulted in predicted probabilities of vascular cognitive impairment of 16%, 43%, 
73% or 95% respectively. We have developed VCING criteria that are reproducible 
and clinically predictive. Assuming our model can be validated in an independent 
dataset, we believe that this will be helpful for neuropathologists in reporting a low, 
intermediate or high likelihood that cerebrovascular disease contributed to cognitive 
impairment. 
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Introduction 
The spectrum of vascular cognitive impairment (VCI) encompasses mild cognitive 
deficits that do not necessarily progress to dementia, and includes post-stroke 
dementia, vascular dementia, subcortical ischaemic vascular dementia, multi-infarct 
dementia and mixed dementias (i.e. co-morbid neurodegenerative and vascular 
pathology) (O'Brien et al., 2003). VCI may be suspected if there is widespread 
disease of cerebral blood vessels (e.g. atherosclerosis, arteriolosclerosis or cerebral 
amyloid angiopathy (CAA), focal or diffuse ischaemic changes or foci of 
haemorrhage, particularly in the absence of an alternative pathological explanation for 
cognitive decline (Ferrer, 2010). However, these pathological abnormalities often 
occur, at least to some degree, without apparent cognitive impairment (Fernando et 
al., 2004; Grinberg and Thal, 2010; Thal et al., 2012) and become more prevalent 
with increased age (Jellinger and Attems, 2010). They are also very common in 
patients with Alzheimer’s disease and other neurodegenerative dementias, and 
probably lower the threshold for neurodegenerative dementia (Esiri et al., 1999; 
Schneider et al., 2009; Schneider et al., 2004). 
Various protocols and definitions have been proposed to identify and categorise 
different types of cerebrovascular pathology in relation to dementia (Chalmers et al., 
2003; Deramecourt et al., 2012; Esiri et al., 1997; Kalaria et al., 2004; Love, 2005; 
Montine et al., 2012; Richardson et al., 2012; Smallwood et al., 2012; Strozyk et al., 
2010). Currently there are no widely accepted neuropathological criteria for the post-
mortem diagnosis of VCI or vascular dementia. This poses a problem for prevalence 
estimates and comparison and collaboration of research and is in contrast to other 
types of dementia, such as Alzheimer’s disease (Braak and Braak, 1991; Mirra et al., 
		
1991) and dementia with Lewy bodies (McKeith et al., 2005). Highlighting these 
issues, a systematic review of neuropathological studies of cerebral microinfarcts in 
the context of vascular disease found large variability in characteristics of 
microinfarcts reported in the different studies and highlighted the obvious need for 
standardization of neuropathological criteria to allow comparison of findings in 
different centres (Brundel et al., 2012). Other surveys of post-mortem 
neuropathological assessment in centres across the world have revealed wide 
differences in the definitions, sampling procedures and interpretation of vascular 
pathology (Alafuzoff et al., 2012; Pantoni et al., 2006). The importance of 
establishing evidence-based, objective criteria for post-mortem evaluation of the 
contribution of cerebrovascular disease to cognitive impairment is widely 
acknowledged (Alafuzoff et al., 2012; Grinberg and Heinsen, 2010; Jellinger, 2008; 
Jellinger, 2013). The aim of the present study was to develop a set of Vascular 
Cognitive Impairment Neuropathology Guidelines (VCING) that represented a 
consensus approach to the post-mortem assessment and scoring of cerebral vascular 
disease in relation to VCI, and was supported by objective evidence of clinical 
relevance. 
 
Materials and methods 
Stage 1: Delphi study 
Fourteen UK-based neuropathologists, mainly from the BDR network 
(http://brainsfordementiaresearch.co.uk), were invited to participate in a survey to 
agree on a protocol to (i) assess and (ii) report cerebrovascular disease, with a view to 
		
(iii) analysing which types of vascular pathology that could be reliably assessed best 
predicted cognitive impairment. Nine neuropathologists accepted the invitation. A 
Delphi survey (Ferri et al., 2005; Linstone, 1975) was conducted using an online 
survey tool (Bristol Online Surveys (https://www.onlinesurveys.ac.uk/) hosted by the 
University of Bristol. Survey responses were anonymous and were collated and 
analysed by an independent facilitator (O. A. S.). Responses informed questions for 
each subsequent round. The questions were presented to participants together with a 
summary of the previous results and comments on areas of agreement and 
disagreement. This process was iterated until consensus was achieved or when over 
half of the respondents agreed on one option amongst several. A two-thirds majority 
was sought for bimodal questions (percentages of respondents are provided where 
appropriate). Nine rounds of the survey were conducted. Rounds 1 and 2 assessed 
familiarity with previously published protocols (and directed participants unfamiliar 
with any protocols to the relevant publications) and prioritised a series of issues that 
should be resolved in order to formulate the VCING (Supplementary Table 1). 
Rounds 3 – 7 achieved agreement on definitions, terminologies and sampling 
procedures, based on published definitions and procedures or suggestions by the 
participants. The last two rounds were used to agree the final integrated protocol, after 
participants had an opportunity to review and comment on previous rounds of the 
survey. 
 
Stage 2: reproducibility study 
		
Nine of the original fourteen neuropathologists agreed to participate in the next two 
stages of the study, which were funded by a Network Cooperation grant from 
Alzheimer’s Research UK. 
The neuropathologists assessed post-mortem brain tissue, according to VCING, blind 
to any previous clinical or pathological diagnoses. 113 cases (52F/61M, age 83.40 ± 
8.95 (55-100)) were obtained from the Oxford brain bank and the Newcastle Brain 
Tissue Resource (NBTR) (Table 1 and Supplementary Table 2). All were Caucasians 
from the regional United Kingdom populations served by the two centres. The cohort 
comprised consecutively collected brains from autopsies with consent for brain 
donation that fulfilled the following criteria. The principal inclusion criterion was 
formal cognitive assessment, in most cases including MMSE, within 12 months of 
death, in a memory or vascular clinic. Exclusion criteria were the presence of 
substantial Alzheimer’s disease (Braak tangle stage > III) (Braak and Braak, 1991), 
Lewy body pathology (Braak Lewy body stage > 3) (McKeith et al., 2005) or other 
non-vascular neurological disease. In 4 cases we could exclude Braak tangle 
pathology of stage IV or higher but did not have adequate histology of the 
transentorhinal region and subiculum for precise staging. The cases included blocks 
of all of the brain regions specified in the VCING protocol. Formalin-fixed paraffin-
embedded sections that were from the VCING-specified brain regions and had been 
stained with haematoxylin and eosin, or luxol fast blue (to assess myelin loss), or 
immunolabelled for Aβ with Chemicon 4G8 (to assess CAA), were circulated 
between the seven participating UK centres. 
Inter-rater reliability was tested by calculating Gwet's AC2 coefficient (Gwet, 2008) 
for each pathology in each region. This method is a more appropriate alternative to 
		
the conventional Kappa’s coefficient when there are marked unbalanced marginal 
totals, i.e. very rare presentation of some pathologies when the majority of samples 
have no pathology. In these scenarios it has been shown that one can have a high level 
of concordance but low Kappa values as a statistical artefact (Feinstein and Cicchetti, 
1990). The calculations were performed using AgreeStat 2015.2 programme 
(Advanced Analytics, LLC). Quadratic weights were assigned for scale scoring 
schemes, a coefficient of 1 indicating full agreement (exact same score by all 
participants). We used the benchmarks proposed by Landis and Koch (Landis and 
Koch, 1977) to evaluate the extent of agreement for the AC2 coefficient (> 0.4 
indicating moderate, > 0.6 substantial and > 0.8 almost perfect agreement). Due to 
small numbers, scoring schemes with more than 2 levels of severity were 
dichotomised to produce more robust parameter estimates maximise for stage 3. 
 
Stage 3: validation study 
Multivariable logistic regression analysis was undertaken to assess the contribution of 
vascular pathologies to cognitive impairment (STATA 14 - StataCorp LP, Texas, 
USA). The primary outcome variable was a clinical diagnosis of dementia or mild 
cognitive impairment (henceforth collectively termed 'cognitive impairment'). As a 
sensitivity analysis, we also ran analyses using a cut-off of MMSE <27 (Pendlebury et 
al., 2012). We calculated the median vascular scores (both region-specific and global) 
across raters for each type of pathology and brain region. Any cases with fewer than 4 
raters per pathology/area were excluded.  
		
We used a two-stage modelling process. We assessed which pathologies in which 
brain regions were associated with both outcomes, initially by univariable regression 
analysis. If multiple brain regions were significantly associated for a particular 
pathology and not highly co-linear, as tested by chi-square analysis, we used a 
stepwise multivariable model to identify in which region(s) the particular pathology 
best predicted cognitive impairment. Bimodal variables were also created for the 
presence of a particular pathology in at least one of the brain regions (termed ‘global’ 
variables). Because of the small sample size, with some cells having zero 
observations, we used exact (exlogistic command in Stata) rather than conventional 
logistic regression. This method uses the conditional distribution of the parameter-
sufﬁcient statistics and the conditional maximum likelihood estimates as an 
alternative to maximum likelihood estimation, which can perform poorly for small 
sample sizes. In addition, where the outcome variable is completed determined by the 
exposure, exlogistic computes the median unbiased estimate, the regression estimate 
that places the observed sufﬁcient statistic at the median of the conditional 
distribution. 
In the second stage, the best predictors from stage 1 were entered into a stepwise 
multivariable regression model with cognitive impairment as the dependent variable. 
The best combined model was used to calculate diagnostic utilities, area under the 
ROC curve and predicted probabilities using the presence and absence of the key 
pathological features. This was then repeated with the secondary outcome (MMSE < 
27). Finally as a post-hoc exploratory analysis, we wanted to see if the predictive 
value of the best model differed by age of the subjects and we tested for age and 
pathology interactions, having dichotomised age at the median. 
		
 
Results 
Stage 1: Delphi study 
In the first survey, we presented previously published protocols for neuropathological 
assessment in suspected vascular dementia, identified by literature review, to the 
participants. Participants were asked to state their familiarity and use of these 
protocols and to critique their utility. Results from Round 1 were presented to the 
participants in the subsequent round. After review of these results, respondents 
selected the best papers upon which to base discussions in order to formulate VCING. 
The 5 most supported (≥ 75%) papers were: Esiri et al., 1997; Strozyk et al., 2010; 
Deramecourt et al., 2012; Montine et al., 2012; and Smallwood et al., 2012. Other 
papers that had been considered were those by Chui et al., 1992; Roman et al., 1993; 
Vinters et al., 2000; Halliday et al., 2002; White et al., 2002; Kalaria et al., 2004; 
Love, 2005; Hachinski et al., 2006; Gold et al., 2007; and the NACC Neuropathology 
Diagnosis Coding Guidebook of the ADC Clinical Task Force and the National 
Alzheimer's Coordinating Center (ADC Clinical Task Force and the National 
Alzheimer's Coordinating Center, 2008). Respondents suggested additions or 
amendments to improve the usefulness of the protocols in the selected papers. The 
consensus was that there should be assessment of vessel wall pathology, separate 
from and additional to assessment of presumed ischaemic tissue damage; both large 
and small vessel disease; haemorrhagic lesions as well as presumed ischaemic ones; 
and that there should be separate scoring systems for quantifying severity of vessel 
wall pathology and tissue damage. 
		
In round 2 participants were also asked to prioritise the immediate and longer term 
objectives of VCING. The immediate objectives selected by ≥ 75% of respondents 
became the focus for Rounds 3-7 (Supplementary Table 1). The topics and key points 
covered in each round are summarised in Supplementary Fig. 1. 
 
Definitions  
Three of the top five immediate objectives were to develop consensus definitions. 
Agreed definitions are presented in Table 2. Greater discussion was required as to the 
distinction between arteriosclerosis and arteriolosclerosis. This was prompted by the 
definition presented in Deramecourt et al., 2012. Although supported by a majority 
(75%) in Round 3, the definition was noted by one participant to relate to 
arteriolosclerosis rather than arteriosclerosis. Another respondent suggested that it 
was sufficient to identify hyaline thickening of the vessel wall with loss of tunica 
media even in the absence of obvious narrowing of the lumen to diagnose 
arteriosclerosis. After review of this feedback, consensus support (67%) was received 
for the definition 'hyaline thickening of walls of vessels < 150 µm in diameter, not 
associated with lipid vacuole-containing cells in the tunica media'. Two respondents 
suggested additions to the agreed definition of arteriolosclerosis that were presented 
to the participants in the following round. A majority (62.5%) of Round 6 respondents 
were in favour of including one of the suggestions: 'Diagnosis requires the absence of 
inflammation, amyloid or fibrinoid necrosis'. 
 
Separate designation of microinfarcts and microhaemorrhages 
		
All Round 3 respondents stated that they could usually distinguish between 
microinfarcts and microhaemorrhages. However, opinion was split (50%) as to 
whether they should all be co-designated as microvascular lesions, as proposed by 
Montine et al., 2012, as this would prevent later determination of the separate 
contribution of these individual types of lesion to cognitive dysfunction. After 
subsequent feedback in Round 4, all respondents agreed that microinfarcts and 
microhaemorrhages should be separately recorded. Microhaemorrhage was 
distinguished from perivascular haemosiderin leakage by the accumulation of 
haemosiderin in the brain parenchyma. 
 
Sampling procedures 
The majority of Round 3 respondents (88%) supported the sampling of a specified set 
of blocks from one hemisphere but with additional sampling of macroscopic lesions. 
All respondents agreed on the utility of staining with HE and LFB. Only 25% of 
respondents supported the additional use of silver impregnation for axons 
(Bielschowsky/Bodian/Palmgren). In addition to the stains listed, immunolabelling of 
Aβ or staining of sections with Congo red was suggested. 86% of Round 4 
respondents thought that sections should routinely be immunolabelled for Aβ and 
57% of respondents suggested the use of Chemicon Clone 4G8 for this. After 
feedback of these results, all respondents in Round 5 agreed to the use of Chemicon 
clone 4G8 for immunolabelling of Aβ. 
A wide range of possible brain regions to be sampled were considered for inclusion in 
VCING. Those supported by a majority (≥ 63%) are listed in Table 3. The subsequent 
		
round elicited additional comments concerned the sampling of cerebral white matter 
regions. 86% of respondents felt that temporal and occipital white matter should be 
adequately represented in the blocks sampled, 86% agreed that the internal capsule 
should be sampled, and 71% agreed that white matter regions should routinely be 
sampled bilaterally in VCING. 
 
Assessing and quantifying vessel wall pathology 
In Round 3 it was agreed that atheroma of the circle of Willis (88%), arteriosclerosis 
(including arteriolosclerosis) (88%) and CAA (100%) should be assessed. 
Respondents in Round 4 indicated which published methods for assessing and 
quantifying these vessel wall pathologies they preferred and/or provided alternative 
suggestions or comments. All Round 4 respondents supported the use of the method 
of Esiri et al., 1997 for scoring atheroma of circle of Willis. All respondents thought 
that the scoring of arteriolosclerosis should be based on the method of Deramecourt et 
al., 2012, that arteriosclerosis and arteriolosclerosis should be scored together (62.5% 
support) and that fibrinoid necrosis and microaneurysms as complications of 
arteriolosclerosis should be separately scored simply as present (1) or absent (0) (75% 
agreement). 
In Round 4, participants were asked to rate three published CAA scoring systems. 
Preference was expressed for the Love et al., 2014 (first choice preference) and Esiri 
et al., 1997 protocols, the latter receiving a higher combined first and second choice 
preference. However, most respondents wanted to take separate account of CAA in 
		
the cortex and meninges, and to assess capillary CAA separately from arteriolar CAA, 
and these preferences were incorporated into a composite CAA scoring system.    
 
Assessing and quantifying tissue damage caused by/associated with vessel 
disease  
Most participants thought that all of the types of putatively 'vascular' tissue damage 
presented in Round 3 should be assessed (≥ 75%). In Round 4, participants were 
asked to rank their preference for the three published systems for scoring tissue 
damage caused by or associated with vessel disease. Deramecourt et al., 2012 was the 
first choice of 71% of respondents. After feedback of these results, this choice was 
endorsed by all Round 5 respondents. However, as the respondents had previously 
agreed on the assessment of lacunar infarcts, larger haemorrhages and 
microhaemorrhages, which are not part of the Deramecourt et al., 2012 protocol, the 
protocol was modified to include these elements and agreed by consensus in the next 
round (Table 3).  
The aim of Round 8 was to review and agree on the final assessment protocol. 
Summary results from Rounds 1-7 were presented and questions posed to confirm 
support or highlight points that still need clarification. The only amendments agreed 
in Round 9 were that CAA should be assessed separately in all 4 lobes of the 
cerebrum and separately in the hippocampus and the other parts of the temporal lobe, 
and that the abnormalities that constituted CAA vasculopathy were agreed to be 
concentric splitting of the vessel wall ('double barrelling'), perivascular haemorrhage, 
fibrinoid necrosis, and thrombosis with recanalisation. The final Delphi consensus 
		
VCING are presented in Table 3. The form that was circulated to assessors is 
available as a supplementary file (Supplementary VCING validation assessment 
form). 
 
Stage 2: reproducibility study 
Inter-rater reliability 
Table 4 shows the Gwet’s AC2 coefficients for the vascular pathologies assessed after 
collapsing the scoring schemes based on clinical relevance. In general, analysis 
showed the VCING criteria to be reproducible, most achieving > 0.8, indicating 
almost perfect agreement. There was variability in assessment of the severity of 
arteriolosclerosis: agreement was high in most brain regions (almost perfect in six, 
substantial in three) but moderate in four brain regions. Reliability in assessing 
microinfarcts also varied: almost perfect in the frontal gyrus, occipital cortex, and 
internal capsule, substantial in seven regions and moderate in three brain regions.  
 
Stage 3: validation study 
The number and percentage of cases with vascular pathologies are detailed in 
Supplementary Table 3. Most pathologies were evident in under 10% of cases in the 
majority of brain regions. Large infarcts were rare (0-4%), as were lacunar infarcts 
except in the putamen (19%). No cases were agreed to have haemorrhage, fibrinoid 
necrosis or microaneurysms. More prevalent pathologies were: arteriolosclerosis (19-
46%) in half of the brain areas assessed; leptomeningeal CAA (25-43%) in four out of 
		
six brain areas assessed; and myelin loss in the occipital (24%) and frontal (40%) 
regions. 
 
Contribution of vascular pathologies to cognitive impairment 
Univariable regression analysis showed seven pathologies − arteriolosclerosis, 
perivascular space dilation, leptomeningeal CAA, myelin loss, microinfarcts, lacunar 
infarcts and large infarcts – to be predictive of cognitive impairment (Table 5) and 
unlikely to be due to chance. Age, gender, APOE, Braak stage were not associated 
with cognitive impairment.  
The best individual predictors were entered into a multivariable regression model to 
identify the best combination of predictors of cognitive impairment. The best 
combination model (model 1) included: at least one large infarct (OR = 6.46, 95% CI 
1.50-27.8, p=0.01) moderate/severe occipital leptomeningeal CAA (OR = 5.49, 95% 
CI 2.17-13.9, p <0.001) and moderate/severe myelin loss in at least one brain region 
(OR = 4.06, 95% CI 1.61-10.2, p <0.001). The model correctly classified 77.9% cases 
as cognitively impaired, but was more specific (92.3%) than sensitive (58.3%) with an 
area under the ROC curve of 78.5%. Predicted probabilities of VCI went from 11%, 
38%, 75% to 95% depending whether there were 0, 1, 2 or 3 of these findings (the 
probabilities for individual combinations are shown in Table 6). 
Replacing myelin loss in model 1 with occipital white matter arteriolosclerosis (a 
more specific indicator of vascular disease) for model 2 was only slightly worse in 
predicting correctly 72.6% cases, but with both reduced sensitivity (54.2%) and 
specificity (86.2%) (area under the ROC curve of 77.4%): at least one large infarct 
		
(OR = 8.97 95% CI 2.16-37.3, p=0.003), moderate/severe occipital leptomeningeal 
CAA (OR = 4.24, 95% CI 1.77-10.1, p=0.001) and moderate/severe arteriolosclerosis 
in occipital white matter (OR= 2.70, 95% CI 1.14-6.40, p=0.02). In model 2, the 
predicted probabilities of VCI went from 16%, 43%, 73% to 95% depending whether 
there were 0, 1, 2 or 3 of these findings (see probabilities for individual combinations 
in Table 6). 
The validated VCING are listed in Supplementary Table 4. Secondary analysis 
showed the same pathologies (apart from large infarcts) to be associated with MMSE 
< 27; however, there were differences as to the brain region in which the pathologies 
best predicted this outcome (Supplementary Table 5). Large infarcts globally did not 
quite reach significance (p = 0.08). Therefore model 1 determinants with MMSE as 
the dependent variable did not perform as well: 69% overall accuracy and 74.2% area 
under the ROC curve. Performance of model 2 was comparable: 68% cases were 
correctly classified cognitively impaired, with an improved sensitivity of 61.5% but 
reduced specificity 75 (area under ROC curve 72.3%). However, only 
moderate/severe arteriolosclerosis in occipital white matter was a determinant of 
MMSE < 27 (OR = 3.97, 95% CI 1.62-9.70, p = 0.001), with neither global large 
infarcts nor occipital leptomeningeal CAA reaching conventional levels of statistical 
significance. 
For model 1 we found evidence for a modest age interaction with moderate/severe 
occipital leptomeningeal CAA (p=0.03) so that the odds ratio was stronger for 
subjects with an age ≥ 85 years than those < 85 years (OR 8.37 versus 3.52). For 
model 2, we found this age interaction to be even stronger with moderate/severe 
occipital leptomeningeal CAA (p = 0.006) (OR 11.4 versus 2.13) and there was a 
		
similar interaction with occipital white matter arteriolosclerosis (p = 0.02) (OR 6.40 
versus 1.93). 
 
Discussion 
Although multiple consensus guidelines have been produced on the post-mortem 
assessment of brain tissue for different diseases that cause dementia, most of the 
diagnostic criteria embedded in those guidelines have been based on a priori 
assumptions as to the most relevant lesions. Those assumptions can be tested in 
subsequent studies, as can the reliability with which the lesions can be assessed, but 
such post hoc studies may not address biases in sampling or assessment that are 
intrinsic to the initial guidelines. Our aim in the present study was to develop 
evidence-based practical guidelines for assessing the contribution of vascular 
pathology to cognitive impairment with reduced sampling bias and good 
reproducibility. We achieved this through several steps. The first involved the 
cooperation of a broad group of neuropathologists with expertise in dementia, in 
agreeing on clearly defined, comprehensive sampling and assessment guidelines, 
without making assumptions as to which types of vessel wall abnormality, ischaemic 
and haemorrhagic parenchymal lesion were more or less likely to be associated with 
dementia. We used Delphi-based methods to develop the VCING, with consensus 
definitions, staining procedures and assessment scoring protocols. Next we performed 
a blinded assessment of the inter-rater reliability of the scoring protocols and used the 
results to refine and simplify the assessments to achieve a high degree of 
reproducibility. Lastly, we applied the refined assessment procedures to a series of 
brains from people with varying degrees of vascular pathology and cognitive 
		
impairment in the absence of significant neurodegenerative disease, to develop a 
simple model for determining the probable contribution of cerebrovascular disease to 
cognitive impairment. 
Several of our findings are in keeping with previous studies of vascular cognitive 
impairment. We found significant associations of cognitive impairment with 
microinfarcts, lacunar infarcts, large infarcts, arteriolosclerosis, perivascular space 
dilation, myelin loss and leptomeningeal CAA. Strozyk et al., 2010 found 
leukoencephalopathy, large infarcts, lacunar infarcts and higher vascular burden 
(combined macroscopic score) to be associated with vascular dementia. In another 
study, vascular dementia was associated with brain infarcts in 66% of cases (Thal et 
al., 2012). Subcortical macroscopic infarcts (Schneider et al., 2009) and lacunar 
infarcts in the thalamus were previously shown to be important predictors of cognitive 
impairment (Gold et al., 2005). Microinfarcts were found in all brain regions assessed 
in VCING – in agreement with a recent systematic review (Brundel et al., 2012). 
Those in the parietal cortex and putamen were predictive of cognitive impairment. 
Previous studies found associations between microinfarcts and dementia or cognitive 
dysfunction (Arvanitakis et al., 2011; Brayne et al., 2009; Esiri et al., 1997; Gold et 
al., 2005; Kovari et al., 2004; Sonnen et al., 2007; Troncoso et al., 2008; White et al., 
2002). Cognitive impairment was also reported to be associated with diffuse white 
matter demyelination (Esiri et al., 1997), periventricular demyelination (Kovari et al., 
2004) and arteriolosclerotic small vessel disease (Ighodaro et al., 2016; Smallwood et 
al., 2012), and several studies found CAA to be associated with cognitive impairment, 
independent of its association with Alzheimer's disease (Greenberg et al., 2004; 
Keage et al., 2009; Neuropathology Group. Medical Research Council Cognitive and 
Aging, 2001; Pfeifer et al., 2002), as shown here. 
		
Individual pathologies predicted cognitive impairment with 60-65% accuracy 
(univariable analysis). Combining the best predictors from three pathologies 
improved this accuracy to 78%: moderate/severe occipital leptomeningeal CAA, at 
least one large (> 10-mm diameter) infarct, and moderate/severe myelin loss in at 
least one brain region (model 1). The predictive probabilities of VCI for this model 
ranged from 11%-95%, depending on which combinations of pathologies were 
present. Our second model, with slightly lower predictive accuracy (77%), combined 
moderate/severe occipital leptomeningeal CAA, at least one large infarct, and 
moderate/severe arteriolosclerosis in the occipital white matter. We interpret the CAA 
and arteriolosclerosis as proxy measures of white matter damage leading to cognitive 
impairment, in agreement with previous findings (Esiri et al., 1997; Greenberg et al., 
2004). Both models in the present study were derived from cases without significant 
neurodegenerative pathology. As myelin loss is not specific for cerebral ischaemia 
and may result from neurodegenerative changes in overlying cerebral cortex (Agosta 
et al., 2011; Coleman, 2005; Leys et al., 1991; McAleese et al., 2015; Tosto et al., 
2015), we favour the second model as all three determinants are specific measures of 
cerebrovascular pathology. Although empirically its performance was slightly worse, 
it was comparable with regard to the area under the ROC curve (77.4% compared 
with 78.5% in the first model) and the probability of cognitive impairment ranged 
from 16% to 95%, depending on the combination of key pathological abnormalities 
present. Interestingly, we observed that the strength of association of some of the 
pathological findings with cognitive impairment may differ in an older as compared 
to younger brain. Our interaction tests were done post hoc and must therefore be 
treated with caution as they may simply reflect a type I error. However, the findings 
are of potential interest and are in keeping with other neuropathological data 
		
suggesting that vascular disease plays an increasingly important role in the 
development of dementia in the very old (Brayne et al., 2009). 
 
Strengths and limitations: Delphi study 
Our initial expectation was that we could use previously published protocols for 
neuropathological assessment in suspected vascular dementia as the basis for the 
present study. However, our literature review indicated that no single published 
protocol covered the full range of relevant pathologies, supporting the need for this 
study. Indeed, even with reference to five different published guidelines, we had 
insufficient detail on definitions of some terms and scoring schemes. The scoring 
protocol for assessing and quantifying tissue damage caused or associated with vessel 
disease by Deramecourt et al., 2012 was adopted for assessment of several of the 
vascular pathologies but participants devised further criteria for scoring lacunar 
infarcts, larger haemorrhage and microhaemorrhages. All respondents supported the 
scoring method of Esiri et al (Esiri et al., 1997) for atheroma of circle of Willis. We 
extended Deramecourt et al., 2012 for arteriolosclerosis with additional scoring of the 
associated complications of fibrinoid necrosis and microaneurysms. scoring schemes 
(Esiri et al., 1997; Love et al., 2014) were adapted for assessment of CAA. 
The underlying principle of the Delphi method is that decisions made through 
iterative review by a group are more likely to be valid than those made by individuals. 
The iterative process was particularly important to reconcile differences in the 
definitions and terminology used by the neuropathologists. However, the participants 
		
held similar views on most topics without the need for repeated rounds of questions, 
for example with reference to which brain regions and pathologies should be assessed. 
 
Strengths and limitations: reproducibility and validation studies 
Strengths of the study were the relatively large number of neuropathologists and the 
combination of cohorts from two UK brain banks, providing cases with a broad range 
of vascular pathology and cognitive performance. Our primary outcome measure was 
cognitive impairment. Although MMSE scores were available for most cases, this test 
is relatively insensitive to the progressive decline and loss of executive function 
typically seen in VCI (Ihara et al., 2013; Pendlebury et al., 2010; Pendlebury et al., 
2012) and we therefore used MMSE scores in secondary analysis. 
Large haemorrhages, microhaemorrhages, fibrinoid necrosis and microaneurysms 
were either rare or not present in this cohort. In consequence, these elements of the 
protocol could not be validated, although is quite possible that some of the rarer 
pathologies may also predict cognitive impairment. High inter-rater reliability for 
these pathologies simply reflected agreement amongst the assessors for the absence of 
pathology in the majority of cases. Modelling and diagnostic predictions could not be 
fully realised due to insufficient numbers for some pathologies in regional analysis; 
however, global measures were employed to overcome this limitation. The models 
presented in the present study are limited by the cohort size and composition of the 
cohort. It will be important to assess the reproducibility of these models in a much 
larger cohort, ideally with standardised prospective collection of clinical and 
cognitive data. 
		
A final limitation of the present study was its reliance solely on morphological 
assessment of vascular pathology. Recent studies have shown that biochemical 
assessments can provide additional information of potential relevance to vascular 
cognitive impairment. Examples include measurement of the concentration of both 
vascular endothelial growth factor and the ratio of myelin-associated glycoprotein to 
proteolipid protein-1 to assess cerebral perfusion (Barker et al., 2014; Love and 
Miners, 2015a; Love and Miners, 2015b; Miners et al., 2015; Thomas et al., 2015), 
and measurement of von Willebrand factor as a marker of microvascular density 
(Miners et al., 2014; Thomas et al., 2015). It is possible that the inclusion of these and 
other biochemical assays, e.g. of vesicular glutamate transporter and choline 
acetyltransferase activity (Kirvell et al., 2010; Sharp et al., 2009) or of 
vasoconstrictors such as endothelin-1 or angiotensin II (Ashby et al., 2016; Barker et 
al., 2014) might enhance neuropathological assessment of the determination of the 
contribution of cerebral vascular disease to cognitive impairment.  
 
  
		
Conclusion 
This study has used consensus VCING to evaluate which vascular pathologies, 
amongst a broad range, best predict cognitive impairment. Our findings suggest that 
neuropathologists can use a combination of the three main determinants – 
moderate/severe occipital leptomeningeal CAA, at least one large infarct, and 
moderate/severe arteriolosclerosis in the occipital white matter – to assign a low, 
intermediate or high likelihood that cerebrovascular disease contributed to cognitive 
impairment in an individual case (Fig. 1). Further validation of the VCING in a larger 
clinical cohort is encouraged.  
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 Table 1  Cohort details: mean age, gender and clinical diagnosis 
 
Cohort details N=113 
Mean age ± SD (range) 83.40 ± 8.95 (55-100) 
Gender (M/F) 61/ 52 
Clinical diagnosis ‘cognitive impairment’: 
Stroke with dementia (11) / with mild dementia (2) 
Dementia 
VaD (3) /probable VaD (3) 
Multi-infarct dementia (MID) 
Possible dementia with white matter disease 
Probable AD (2) / Possible AD (3) 
Possible DLB 
Mild dementia with parkinsonism or AD or DLB 
Psychiatric disorder/dementia 
Mild cognitive impairment 
 
Clinical diagnosis ‘no cognitive impairment’: 
Cognitively normal (healthy) 
Cognitively normal (study-irrelevant health problems)  
Stroke, no dementia  
Cardiovascular disease 
Parkinson's disease 
Psychiatric illness  
Mental 'lethargy' 
 
48: 
13 
9 
6 
1 
1 
5 
1 
1 
3 
8 
 
65: 
31 
5 
16 
2 
2 
8 
1 
 
MMSE score mean ± SD (range)  (n = 100) 
MMSE score <27/ ≥27 
23.03 ± 7.05 (0-30) 
48/ 52 
Braak stage: 0  
                     I-II 
                     III-IV 
8 
76 
26 
Genotype data (n = 77) 
APOE ε4 allele frequency  
APOE ε2 allele frequency  
 
0.14 
0.06 
		
 
Table 2: Delphi study agreed definitions. Definitions were developed amongst respondents 
through multiple survey rounds, apart from those denoted * that were taken from Strozyk et 
al. (Strozyk et al., 2010). 
 
  
Agreed definitions 
Atherosclerosis/atheroma  
Disease of medium-sized to large arteries at the base of the brain, 
characterised by formation of plaques showing varying degrees of 
destruction of the vessel wall and accumulation of lymphocytes and 
macrophages; in later stages plaques may contain necrotic core, 
cholesterol clefts and foci of calcification. 
Arteriolosclerosis 
Hyaline thickening of walls of vessels <150µm in diameter, not 
associated with lipid-containing cells replacing the tunica media. 
Diagnosis requires an absence of intramural inflammation, amyloid or 
fibrinoid necrosis. 
Large infarct Maximum diameter >1 cm*. 
Lacunar infarct  Cystic lesion visible to the naked eye but <1 cm in diameter*. 
Microinfarct Ischaemic lesion found on microscopic examination but not visible to 
the naked eye*. 
Large haemorrhage  Haemorrhagic lesion visible to the naked eye which is easily identifiable 
on macroscopic examination. 
Microhaemorrhage  Haemorrhagic lesion (with parenchymal involvement) found on 
microscopic examination which is not visible to the naked eye. 
White matter pallor A reduction in myelin staining in white matter in Luxol fast blue stained 
sections. 
White matter rarefaction Weakly stained/pale and loose appearance of myelinated fibres. 
		
 
Table 3: Pathologies and brain areas agreed for assessment after Delphi process. 
 
Samples are taken from the specified regions in one hemisphere with additional 
sampling of macroscopic lesions. Temporal and occipital white matter should be 
adequately represented in the blocks sampled. Scoring schemes for arteriolosclerosis, 
dilatation of perivascular spaces, and infarcts were adapted from Deramecourt et al 
(Deramecourt et al., 2012)*; for CAA from Esiri et al 1997 (Esiri et al., 1997) and (Love 
et al., 2014)#, with CAA-associated vasculopathic changes given a score of 4; for 
assessment of atheroma of circle of Willis from Esiri, Wilcock and Morris (Esiri et al., 
1997)$. 
 
Pathology Brain areas assessed 
Arteriolosclerosis (0-3)* 
All four lobes of cerebrum (frontal and 
occipital white matter scored separately) 
Hippocampus (anterior and posterior scored 
separately) 
Basal ganglia (caudate, globus pallidus, 
internal capsule and putamen scored 
separately) 
Thalamus 
Fibrinoid necrosis (0/1) 
Microaneurysms (0/1) 
Perivascular space dilation (0-3)* 
Perivascular haemosiderin leakage (0-3)* 
Microinfarcts (0/1)* 
Lacunar infarcts (0-3)  
Large infarcts (0/1)*  
Microhaemorrhage (0/1)  
Larger haemorrhage (0/1) 
CAA
#
;  
leptomeningeal (0-4) 
cortical (0-4)  
capillary (0/1)  
All four lobes of cerebrum, with separate 
scores for hippocampus and temporal 
neocortex 
Myelin loss (0-3)* 
Internal capsule, frontal white matter and 
occipital white matter 
Atheroma of circle of Willis
$  
		
 
Table 4: Inter-rater reliability in assessment of each vascular pathology in each brain region.  
 
Brain region Arteriolosclerosis Fibrinoid necrosis Microaneursyms 
Perivascular  
space dilation 
Perivascular 
haemosiderin leakage 
Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. 
Frontal cortex 0.91 0.89 to 0.93 0.95 0.93 to 0.97 0.99 0.98 to 1 0.99 0.97 to 1 0.98 0.96 to 0.99 
Frontal white matter 0.45 0.38 to 0.53 0.82 0.79 to 0.86 0.94 0.92 to 0.96 0.81 0.76 to 0.86 0.79 0.74 to 0.85 
Temporal cortex 0.87 0.84 to 0.91 0.93 0.90 to 0.96 0.99 0.97 to 1 0.98 0.96 to 1 0.92 0.88 to 0.95 
Occipital cortex 0.90 0.88 to 0.93 0.96 0.94 to 0.98 0.99 0.99 to 1 0.99 0.99 to 1 0.96 0.94 to 0.98 
Occipital white matter 0.52 0.46 to 0.59 0.88 0.85 to 0.91 0.96 0.95 to 0.98 0.84 0.80 to 0.89 0.81 0.76 to 0.86 
Parietal cortex 0.78 0.74 to 0.83 0.91 0.88 to 0.94 0.95 0.93 to 0.98 0.95 0.92 to 0.98 0.82 0.77 to 0.88 
Anterior Hippocampus 0.89 0.85 to 0.93 0.92 0.87 to 0.96 0.98 0.95 to 1 0.98 0.94 to 1 0.97 0.93 to 1 
Post hippocampus 0.89 0.86 to 0.93 0.91 0.88 to 0.95 0.98 0.96 to 1 0.98 0.95 to 1 0.96 0.92 to 0.99 
Caudate 0.73 0.68 to 0.78 0.87 0.83 to 0.90 0.95 0.92 to 0.97 0.95 0.92 to 0.98 0.98 0.96 to 1 
Putamen 0.50 0.43 to 0.57 0.80 0.75 to 0.84 0.86 0.82 to 0.90 0.81 0.76 to 0.87 0.90 0.87 to 0.93 
Internal capsule 0.88 0.86 to 0.91 0.95 0.92 to 0.97 0.97 0.95 to 0.98 0.99 0.99 to 1 0.98 0.97 to 0.99 
Globus pallidus 0.53 0.46 to 0.61 0.86 0.82 to 0.90 0.94 0.91 to 0.97 0.87 0.83 to 0.92 0.92 0.88 to 0.95 
Thalamus 0.68 0.63 to 0.74 0.79 0.74 to 0.83 0.86 0.82 to 0.90 0.90 0.86 to 0.94 0.96 0.93 to 0.98 
 
 
 
 
 
 
		
 
 
 
Brain region Microinfarct Large infarct Lacunar infarct Microhaemorrhage Larger haemorrhage 
Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. 
Frontal cortex 0.84 0.78 to 0.89 0.98 0.96 to 0.99 0.99 0.99 to 1 0.98 0.97 to 1 0.99 0.98 to 1 
Frontal white matter 0.57 0.52 to 0.62 0.93 0.89 to 0.96 0.95 0.93 to 0.97 0.95 0.93 to 0.98 0.99 0.98 to 1 
Temporal cortex 0.75 0.70 to 0.81 0.95 0.92 to 0.98 0.99 0.97 to 1 0.98 0.96 to 1 0.99 0.973 to 1 
Occipital cortex 0.83 0.79 to 0.88 0.98 0.96 to 1 1.00 0.99 to 1 0.98 0.97 to 1 1.00 0.99 to 1 
Occipital white matter 0.60 0.56 to 0.64 0.97 0.94 to 0.99 0.97 0.95 to 0.98 0.95 0.92 to 0.97 0.99 0.98 to 1 
Parietal cortex 0.71 0.65 to 0.78 0.95 0.92 to 0.98 0.98 0.95 to 1 0.96 0.93 to 0.99 0.99 0.97 to 1 
Anterior Hippocampus 0.64 0.58 to 0.69 0.98 0.94 to 1 0.99 0.96 to 1 0.99 0.94 to 1 1.00 0.99 to 1 
Post hippocampus 0.60 0.55 to 0.65 0.97 0.94 to 1 0.99 0.98 to 1 0.99 0.97 to 1 1.00 0.99 to 1 
Caudate 0.64 0.59 to 0.69 0.98 0.96 to 1 0.93 0.91 to 0.96 0.97 0.95 to 1 1.00 0.98 to 1 
Putamen 0.52 0.45 to 0.59 0.91 0.87 to 0.95 0.81 0.76 to 0.86 0.96 0.95 to 0.98 1.00 0.99 to 1 
Internal capsule 0.81 0.77 to 0.85 0.97 0.95 to 0.99 0.99 0.98 to 1 0.99 0.99 to 1 1.00 0.99 to 1 
Globus pallidus 0.65 0.59 to 0.71 0.95 0.92 to 0.98 0.85 0.81 to 0.89 0.98 0.95 to 1 0.99 0.97 to 1 
Thalamus 0.55 0.49 to 0.61 0.96 0.94 to 0.98 0.87 0.84 to 0.91 0.92 0.89 to 0.95 1.00 0.99 to 1 
 
 
 
 
 
 
		
 
 
 
 
Brain region Leptomeningeal CAA Cortical CAA Capillary CAA Myelin loss 
Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. 
Frontal cortex 0.89 0.85 to 0.93 0.96 0.93 to 0.98 0.92 0.89 to 0.96 Not scored 
Frontal white matter Not scored Not scored Not scored 0.75 0.70 to 0.80 
Temporal cortex 0.91 0.87 to 0.95 0.96 0.94 to 0.99 0.92 0.87 to 0.96 Not scored 
Occipital cortex 0.84 0.78 to 0.90 0.92 0.89 to 0.96 0.84 0.79 to 0.90 Not scored 
Occipital white matter Not scored Not scored Not scored 0.82 0.77 to 0.87 
Parietal cortex 0.91 0.88 to 0.95 0.95 0.93 to 0.98 0.93 0.90 to 0.96 Not scored 
Anterior Hippocampus 0.95 0.90 to 0.99 0.97 0.93 to 1 0.95 0.91 to 1 Not scored 
Post hippocampus 0.93 0.88 to 0.98 0.97 0.94 to 1 0.96 0.92 to 1 Not scored 
Caudate Not scored Not scored Not scored Not scored 
Putamen Not scored Not scored Not scored Not scored 
Internal capsule 
      
0.95 0.93 to 0.97 
Globus pallidus Not scored Not scored Not scored Not scored 
Thalamus Not scored Not scored Not scored Not scored 
 
Gwet’s AC2 coefficient (Coefficient), 95% confidence interval (CI). P-value <0.001 for all collapsed scores. 
 
Table 5: Brain region-specific univariable logistic regression, showing significant associations with 
cognitive impairment.  
 
Pathology§ Brain region Normal (%) 
N= 65  
Cognitively 
impaired 
(%) 
N= 48  
Odds Ratio 95% C.I. p - value 
Arteriolosclerosis Occipital white matter 18 (28) 26 (54) 3.09 1.41-6.78 0.005 
 
Global 45 (69) 43 (90) 3.82 1.32-11.09 0.008 
Leptomeningeal CAA Occipital  20 (31) 29 (60) 3.43 1.57-7.51 0.002 
Leptomeningeal CAA
#
 Occipital 8 (12) 16 (33) 1.89 1.17-3.04 0.009 
Leptomeningeal CAA Global 27 (42) 31 (65) 2.57 1.19-5.54 0.02 
Myelin loss Occipital white matter 10 (15) 17 (35) 3.02 1.23-7.39 0.02 
 
Frontal white matter 20 (31) 25 (52) 2.45 1.13-5.30 0.02 
 
Global 23 (35)  33 (69) 4.02 1.82-8.89 0.001 
Myelin loss# Frontal white matter 2 (3) 7 (15) 5.38 1.06-27.17 0.04 
Microinfarcts Parietal cortex 2 (3) 8 (17) 6.63 1.34-32.88 0.02 
 
Putamen 4 (6) 11 (23) 4.53 1.35-15.28 0.02 
 
Global 23 (35) 27 (56) 2.35 1.09-5.04 0.03 
Lacunar infarcts Thalamus 0 6 (13) *12.8 1.79-∞ 0.008 
Large infarcts Global 3 (5) 12 (25) 6.89 1.82-26.05 0.004 
Perivascular  
space dilation 
      
Global 5 (8) 12 (25) 4.00 1.30-12.29 0.02 
 
§Classified as present versus absent. 
# Leptomeningeal CAA and myelin loss reclassified as severe versus none or mild.  
*Exact logistic regression used to estimate the odds ratio as cells with null value. 
‘Global’ refers to the pathology in at least one brain region. 	
  
		
 
Table 6: Predictive probabilities of cognitive impairment given the presence or absence of pathology. 
 
Model 1 
Group Probability 
	
Global	large	infarcts	 
 
Occipital 
leptomeningeal	CAA	 Global	myelin	loss 
1 0.11 0 0 0 
2 0.34 0 0 1 
3 0.41 0 1 0 
4 0.45 1 0 0 
5 0.74 0 1 1 
6 0.77 1 0 1 
7 0.82 1 1 0 
8 0.95 1 1 1 
 
Model 2 
Group Probability 
	
Global	large	infarcts	 
 
Occipital 
leptomeningeal	CAA 
Occipital	white	matter	
arteriolosclerosis 
1 0.16 0 0 0 
2 0.34 0 0 1 
3 0.45 0 1 0 
4 0.63 1 0 0 
5 0.69 0 1 1 
6 0.82 1 0 1 
7 0.88 1 1 0 
8 0.95 1 1 1 	
		
Figure 
 
Fig. 1:  VCING model estimating the likelihood that cerebrovascular disease contributed to cognitive impairment. Combinations of the three main determinants 
− at least one large (> 10-mm diameter) infarct, moderate/severe occipital leptomeningeal CAA, and moderate/severe arteriolosclerosis in the occipital white 
matter − are used to assign a low, intermediate or high likelihood that cerebrovascular disease contributed to cognitive impairment in an individual case. The 
bars in the upper, middle and lower photomicrographs represent 1 mm, 250 µm and 100 µm respectively. 
 Supplementary Table 1: Immediate and later objectives of Delphi study (≥ 63% 
support by respondents) 
Immediate objectives: 
Definitions of parenchymal lesions attributable to cerebrovascular or systemic vascular disease (100%) 
Definitions of pathology of cerebral blood vessels (88%) 
Terminology for descriptions (88%) 
Terminology for diagnosis (88%) 
Definitions of vascular brain lesions (88%) 
Sampling procedures (75%) 
Consensus nomenclatures (75%) 
Definitions of cerebral vessel disorders (63%) 
Staining/immunostaining procedures (63%) 
Consensus assessment protocols (63%) 
Later objectives: 
Correlation with MRI scan/clinical findings (88%) 
Validation and universal adoption (75%) 
Measurement/quantification of pathology (63%) 
Which neuropathological lesions are functionally significant (63%) 
Thresholds for causative lesions (63%) 
 
 
  
Supplementary Table 2: List of individual cases. 
 
Case no Gender Age APOE Braak 
score 
MMSE Listed cause of death Centre Cognitive 
impairment 
1 M 77 23 II 30 Congestive cardiac 
failure 
Oxford No 
2 M 78 33 0 22 Acute subdural 
haematoma 
Oxford No 
3 F 81 33 II 26 Peritoneal 
carcinomatosis 
Oxford No 
4 F 73 33 I 30 Renal failure Oxford No 
5 F 80 34 II 30 Post-op coronary bypass 
surgery 
Oxford No 
6 M 77 34 II 6 Bronchopneumonia Oxford Yes 
7 F 87 33 II 28 Multiple pulmonary 
emboli 
Oxford No 
8 M 79 33 II 24 Urinary tract infection Oxford No 
9 M 86 23 II 27 Bronchopneumonia Oxford No 
10 M 86 33 II 28 Not known Oxford Yes 
11 M 87 23 II 28 Ruptured aortic 
aneurysm 
Oxford No 
12 F 79 33 II 30 Endometrial cardinoma, 
pulmonary emboli 
Oxford No 
13 M 83 33 II 29 Bowel carcinoma with 
metastases 
Oxford No 
14 M 76 33 II 28 Ischaemic heart disease Oxford No 
15 F 71 24 II 17 Urinary tract infection Oxford Yes 
16 F 85 n/a II 24 Carcinomatosis Oxford Yes 
17 F 94 33 II 23 Acute cerebral 
infarction 
Oxford Yes 
18 F 85 33 II 13 Urinary tract infection Oxford No 
19 M 88 33 II 28 Carcinomatosis Oxford No 
20 M 86 33 II 15 Bronchopneumonia Oxford Yes 
21 F 100 34 II 30 Cardiac failure Oxford No 
22 M 92 33 II 24 Congestive cardiac 
failure 
Oxford No 
23 M 69 n/a II n/a Multi-infarct dementia Newcastle Yes 
24 F 84 n/a II 30 Rectal carcinoma Oxford No 
25 M 55 n/a 0 28 Liver cancer Newcastle No 
26 M 87 34 <VI n/a Bronchopneumonia, hip 
fracture 
Newcastle No 
27 F 88 33 II 29 Bronchopneumonia Oxford No 
28 M 83 n/a 0 n/a Bronchopneumonia Newcastle Yes 
29 F 87 3,4 III 16 Pulmonary emboli Newcastle Yes 
30 F 89 n/a III 29 Ischaemic bowel and 
multi organ failure 
Newcastle No 
31 F 87 n/a III n/a Bronchopneumonia Newcastle Yes 
32 M 68 33 II 30 Myocardial infarction Oxford No 
33 F 86 n/a III n/a Not known Newcastle Yes 
34 F 96 n/a III 27 Acute subdural 
haematoma, atrial 
fibrillation 
Newcastle No 
35 M 88 n/a <VI 9 Probable brain stem 
infarct whilst 
undergoing surgery 
Newcastle Yes 
36 M 77 33 II 29 Probable myocardial 
infarct 
Newcastle No 
37 M 97 n/a <VI n/a Not known Newcastle Yes 
38 M 72 n/a III n/a Stroke Newcastle Yes 
39 M 81 n/a I 12 Not known Newcastle Yes 
40 M 60 n/a II 20 Bronchopneumonia, 
cardiac arrest 
Newcastle Yes 
41 F 91 33 I n/a Aspiration pneumonia Newcastle Yes 
42 M 91 33 I 20 Chest infection Newcastle Yes 
43 F 71 33 III 12 Probable stroke Newcastle Yes 
44 F 97 34 II 22 Pneumonia Newcastle No 
45 M 75 n/a III 11 Bronchopneumonia Newcastle Yes 
46 M 84 n/a I n/a Diverticulitis with 
perforation 
Newcastle Yes 
47 F 78 n/a 0 28 Metastatic cancer, 
probably ovarian 
Newcastle No 
48 M 94 34 I 22 Pneumonia Newcastle Yes 
49 F 88 33 I 16 Ischaemic heart disease, 
recurrent urinary tract 
infection 
Newcastle Yes 
50 F 74 33 III 29 Bronchopneumonia Newcastle No 
51 F 94 n/a II 29 Left ventricular failure, 
ischaemic Heart Disease 
Newcastle No 
52 F 92 33 II 17 Pneumonia Newcastle Yes 
53 M 75 33 II 12 Pneumonia Newcastle Yes 
54 F 90 33 II 19 Not known Newcastle Yes 
55 F 82 34 III 18 Pneumonia Newcastle Yes 
56 F 96 33 II 21 Stroke and left 
ventricular failure 
Newcastle Yes 
57 M 84 34 III 28 Pneumonia, chronic 
renal failure 
Newcastle No 
58 M 87 n/a III 25 Not known Newcastle Yes 
59 F 93 33 III 13 Cardiac arrest ischaemic 
heart disease 
Newcastle Yes 
60 F 95 n/a III 30 Ischaemic bowel Newcastle No 
61 M 82 34 III 26 Cardiac arrhythmia, 
severe coronary artery 
atherosclerosis and 
ischaemic heart disease 
Newcastle No 
62 M 88 33 II 21 Chest Infection Newcastle No 
63 M 96 23 III 13 Frailty of old age, 
dementia 
Newcastle Yes 
64 F 92 n/a II 24 Cardiac arrest, severe 
coronary artery 
atherosclerosis, chronic 
ischaemic heart disease 
Newcastle Yes 
65 F 79 n/a 0 n/a Bronchopneumonia, 
cardiac arrest 
Newcastle Yes 
66 F 98 33 III 17 Frailty of old age, 
cardiac arrest 
Newcastle Yes 
67 F 95 24 II 27 Not known Oxford No 
68 F 89 n/a III 25 Peritonitis Newcastle No 
69 M 83 33 II 12 Metastatic carcinoma of 
rectum 
Newcastle Yes 
70 F 91 23 I 29 Heart failure, chest 
infection 
Newcastle No 
71 F 74 33 I 27 Lung carcinoma Newcastle No 
72 F 91 n/a III n/a Ischaemic heart disease, 
coronary athersclerosis 
and thrombosis 
Newcastle Yes 
73 M 73 n/a II n/a Probable stroke Newcastle Yes 
74 F 88 n/a III 27 Aspiration pneumonia, 
anterior circulation 
stroke 
Newcastle No 
75 M 92 33 III 28 Frailty of age Newcastle No 
76 M 93 33 II 10 Not known Newcastle No 
77 M 87 n/a II 20 Strokes Newcastle Yes 
78 M 81 n/a III 10 Not known Newcastle Yes 
79 M 70 n/a 0 27 Not known Newcastle No 
80 M 88 23 II 29 Pulmonary embolus, 
pancreatic cance, intra-
abdominal metastases 
Newcastle No 
81 M 85 33 II 29 Pneumonia, renal 
failure 
Newcastle No 
82 M 70 n/a II 27 Pneumonia, delirium Newcastle No 
83 M 95 33 II 15 Frailty of old age Newcastle Yes 
84 M 81 n/a II 29 Pneumonia,iInfective 
endocarditis 
Newcastle No 
85 M 93 33 II 9 Congestive cardiac 
failure 
Oxford Yes 
86 M 78 n/a III 18 Not known Newcastle Yes 
87 M 82 3,4 III 25 Heart failure Newcastle No 
88 F 94 n/a II 27 Not known Newcastle No 
89 M 73 n/a 0 30 Peritonitis, perforated 
viscus 
Newcastle No 
90 F 88 3,4 III 26 Respiratory failure - 
exacerbation of COPD 
Newcastle No 
91 F 90 33 II 17 Bronchopneumonia Oxford Yes 
92 F 71 33 II 13 Acute cerebral 
infarction 
Oxford Yes 
93 F 81 33 II 24 Bronchopneumonia Oxford No 
94 M 82 n/a III n/a Bronchopneumonia, 
cardiac arrest 
Newcastle Yes 
95 M 67 33 0 26 Carcinoma of lung Oxford No 
96 M 65 33 II 26 Myocardial infarction Oxford Yes 
97 F 79 33 II 30 Carcinoma of 
oesophagus 
Oxford No 
98 M 80 33 II 29 Not known Oxford No 
99 M 69 34 II 27 Food inhalation Oxford No 
100 M 85 33 II 29 Ruptured aortic 
aneurysm 
Oxford No 
101 F 92 33 II 0 Pulmonary emboli Oxford Yes 
102 F 78 34 II 21 Myocardial infarct Oxford No 
103 F 76 34 II 29 Ischaemic heart disease Oxford No 
104 M 78 23 II 25 Bronchopneumonia Oxford No 
105 F 79 44 II 30 Bronchopneumonia Oxford No 
106 F 92 33 II 16 Old age, cerebral infarct Oxford Yes 
107 F 99 33 II 29 Cardiac failure Oxford No 
108 F 85 34 II 29 Carcinoma of lung Oxford No 
109 M 80 34 II 29 Metastatic prostate 
carcinoma 
Oxford No 
110 M 91 33 II 10 Pericarditis, congestive 
cardiac fauilure 
Oxford Yes 
111 M 77 34 II 30 Myocardial infarction Oxford No 
112 M 76 33 II 28 Myocardial infarction Oxford No 
113 M 68 n/a II 28 Complications of 
coronary surgery 
Newcastle No 
 
Supplementary Table 3: Number (percentage) of cases with each vascular pathology in each brain region. 
Brain region Arteriolosclerosis 
Perivascular 
space dilation 
Perivascular 
haemosiderin 
leakage Microinfarcts 
Lacunar 
infarcts 
Large 
infarcts 
Leptomeningeal 
CAA 
Cortical 
CAA 
Capillary 
CAA 
Myelin 
loss 
Frontal cortex 1 (1%) 0 0 5 (4%) 0 1 (1%) 37 (33%) 16 (14%) 5 (4%) Not scored 
Frontal white matter 52 (46%) 6 (5%) 16 (14%) 8 (7%) 4 (4%) 3 (3%) Not scored Not scored Not scored 45 (40%) 
Temporal cortex 3 (3%) 0 1 (1%) 2 (2%) 0 3 (3%) 27 (25%) 12 (11%) 5 (5%) Not scored 
Occipital cortex 0 0 0 3 (3%) 0 5 (4%) 49 (43%) 17 (15%) 13 (12%) Not scored 
Occipital white 
matter 44 (39%) 4 (4%) 8 (7%) 2 (2%) 1 (1%) 5 (4%) Not scored Not scored Not scored 27 (24%) 
Parietal cortex 8 (7%) 2 (2%) 6 (5%) 10 (9%) 0 1 (1%) 29 (26%) 11 (10%) 5 (5%) Not scored 
Anterior 
hippocampus 3 (3%) 0 0 5 (5%) 0 1 (1%) 9 (9%) 2 (2%) 2 (2%) Not scored 
Posterior 
hippocampus 3 (3%) 0 0 7 (6%) 0 0  13 (12%) 5 (5%) 2 (2%) Not scored 
Caudate 21 (19%) 0 0 5 (4%) 3 (3%) 0 Not scored Not scored Not scored Not scored 
Putamen 44 (39%) 10 (9%) 5 (4%) 15 (13%) 21 (19%) 5 (4%) Not scored Not scored Not scored Not scored 
Internal capsule 3 (3%) 0 0 1 (1%) 0 1 (1%) Not scored Not scored Not scored 3 (3%) 
Globus pallidus 41 (37%) 2 (2%) 5 (5%) 3 (3%) 5 (5%) 3 (3%) Not scored Not scored Not scored Not scored 
Thalamus 24 (22%) 1 (1%) 2 (2%) 12 (10%) 6 (5%) 0 Not scored Not scored Not scored Not scored 
 
Supplementary Table 4: VCING scoring scheme used for the validation multivariable analysis. 
Validated VCING scoring scheme 
Arteriosclerosis and arteriolosclerosis 0 = normal or mild thickening of the vessel media, mild fibrosis  
1 = partial loss of smooth muscle cells in the media and moderate hyaline fibrosis, or complete 
loss of smooth muscle cells in the media with severe hyaline fibrosis and lumen stenosis 
Fibrinoid necrosis and microaneurysms 0 = absent 
1 = present 
Perivascular space dilation 0 = minimal dilatation, or perivascular space ≥ vessel diameter for only a minority of arterioles 
1 = perivascular space ≥ vessel diameter for majority of arterioles 
Perivascular haemosiderin leakage 0 = absent or < 3 haemosiderin granule deposits in perivascular space 
1 = ≥ 3 haemosiderin deposits in perivascular space 
Microinfarcts, lacunar infarcts, large infarcts,  
microhaemorrhage, larger haemorrhage 
0 = absent 
1 = present 
Leptomeningeal and cortical arteriolar CAA: 
 
 
 
Capillary CAA: 
0 = absent, trace, or occasional vessel affected  
1 = several vessels circumferentially affected, or widespread involvement of circumferentially 
affected vessels, or CAA with secondary changes (concentric splitting, haemorrhage, 
fibrinoid necrosis, recanalisation) 
0 = absent 
1 = present 
Myelin loss:  0 = dense and homogeneous myelin staining, mild diffuse or focal myelin pallor 
1 = severe focal/diffuse myelin pallor with vacuolation or tigroid appearance of white matter, or 
total focal/diffuse destruction of myelin, or white matter infarcts 		
Supplementary Table 5: Brain region-specific univariable logistic regression, showing 
significant associations with MMSE <27. 	
Pathology§ Brain region 
Normal 
(%) 
 
N=52 
Cognitive 
impairment 
(%) 
N=48 
Odds 
Ratio 95% C.I. p - value 
Arteriolosclerosis Frontal white matter 16 (33) 31 (60) 2.95 1.31-6.68 0.009 
 Occipital white matter 11 (23) 30 (58) 4.59 1.92 -10.94 0.001 
 Putamen 12 (25) 24 (46) 2.57 1.10-6.02 0.03 
 Thalamus 5 (10) 16 (31) 3.82 1.28-11.45 0.02 
 Global 30 (62) 46 (89) 4.60 1.64-12.91 0.004 
Leptomeningeal 
CAA# Occipital  6 (13) 15 (29) 1.69 1-2.84 0.05 
Myelin loss Frontal white matter 10 (21) 29 (56) 4.79 1.98-11.62 0.001 
 Global 13 (27) 33 (64) 4.68 2-11 <0.001 
Microinfarct Putamen 3 (6) 12 (23) 4.50 1.18-17.10 0.027 
 Global 14 (29) 30 (58) 3.32 1.44-7.60 0.005 
Lacunar infarcts Thalamus 0 5 (10) 6.65 0.88-∞ 0.07 
Perivascular  
space dilation 
Putamen 1 (2) 8 (15) 8.55 1.03-71.13 0.047 
Global 3 (6) 11 (21) 4.02 1.05-15.45 0.042 
 
§Classified as present versus absent 
# Leptomeningeal CAA reclassified as severe versus none or mild.  
*Exact logistic regression used to estimate the odds ratio. 
‘Global’ refers to the pathology in at least one brain region. 
 
 
Supplementary	VCING	validation	assessment	form	
 
VCING assessment form 
Assessing and quantifying vessel wall pathology 
Please refer to the VCING Delphi protocol agreed definitions: 
Arteriolosclerosis = Hyaline thickening of walls of vessels <150µm in diameter, not associated with lipid-containing cells replacing the tunica media. Diagnosis 
requires an absence of intramural inflammation, amyloid or fibrinoid necrosis. 
Atherosclerosis/atheroma = Disease of medium-sized to large arteries at the base of the brain, characterised by formation of plaques showing varying degrees of 
destruction of the vessel wall and accumulation of lymphocytes and macrophages; in later stages plaques may contain necrotic core, cholesterol clefts and foci of 
calcification. 
  
Scoring key for respective vessel wall pathology: 
Arteriolosclerosis/arteriosclerosis (Deramecourt 2011 adapted):  
0= Normal  
1= Mild thickening of the vessel media, mild fibrosis  
2= Partial loss of smooth muscle cells in the media, moderate hyaline fibrosis  
3= Complete loss of smooth muscle cells in the media, severe hyaline fibrosis, lumen stenosis 
Fibrinoid necrosis and microaneurysms (as complications of arteriolosclerosis): 
0= absent 
1= present 
  
Cerebral amyloid angiopathy (CAA) 
These assessments are to be made in all 4 main lobes and hippocampus. Separate assessment of leptomeningeal and cortical vessels on a 4 point scale, as well as 
recording of presence or absence of capillary CAA: 
0= absent 
1= trace or occasional vessel affected 
2= one or a few vessels circumferentially affected 
3= widespread involvement of circumferentially affected vessels 
4= as 3, with secondary changes  
 
 
Please	record	the	iden/ﬁca/on	number	of	the	case	you	are	assessing	and	your	name	at	the	top	of	the	form	
Please	base	your	score	upon	the	
overall	impression	in	the	sec/on	
rather	than	the	worst	vessel		
Supplementary	VCING	validation	assessment	form	
  
	
	
	Arteriolosclerosis	
0-3	
	
	Fibrinoid	necrosis	
0/1	
	
	Microaneurysms	
0/1	
	
	Leptomeningeal	
CAA	
0-4	
	
	Cor>cal	CAA	
0-4	
	
	Capillary	CAA	
0/1	
	
	Comments		 		
		
Superior	&	middle	
frontal	gyri	 			score					 							score	 score					 			score					 							score	 score					
Superior	&	middle	
temporal	gyri	 			score					 							score	 score					 			score					 							score	 score					
Anterior	
Hippocampus	&	
entorhinal	cortex	
			score					 							score	 score					 			score					 							score	 score					
Posterior	
hippocampus	 			score					 							score	 score					 			score					 							score	 score					
Occipital	cortex	
inc.	Calcarine	
cortex	(BA17	&	18)	
			score					 							score	 score					 			score					 							score	 score					
Inferior	parietal	
lobule	 			score					 							score	 score					
			score				 							score score				 
Frontal	white	
maJer	 			score					 							score	 score					
							 							 				
Caudate	nucleus	 			score					 							score	 score					 							 							 				
Globus	pallidus	 			score					 							score	 score					 							 							 				
Internal	capsule	 			score					 							score	 score					 							 							 				
Putamen	 			score					 							score	 score					 							 							 				
Thalamus	 			score					 							score	 score					 							 							 				
Occipital	white	
maJer	 			score					 							score	 score					
							 							 				
Case	ID:	 Assessor:	
Supplementary	VCING	validation	assessment	form	
 
Assessing and quantifying tissue damage caused by/associated with vessel disease 
Please refer to the VCING Delphi protocol agreed definitions: 
Large infarct (also called macroinfarct) = Maximum diameter >1 cm (Strozyk 2010) 
Lacunar infarct = Cystic lesion visible to the naked eye but <1 cm in diameter (Strozyk 2010) 
Microinfarct = Ischaemic lesion found on microscopic examination but not visible to the naked eye (Strozyk 2010) 
Microhaemorrhage = Haemorrhagic lesion found on microscopic examination which is not visible to the naked eye 
Larger haemorrhage = Haemorrhagic lesion visible to the naked eye which is easily identifiable on macroscopic examination 
White matter pallor = A reduction in myelin staining in white matter in Luxol fast blue stained sections 
White matter rarefaction = weakly stained/pale and loose appearance of myelinated fibres 
  
Scoring Key - VCING adaptation of the Staging of cerebrovascular pathology in dementia 
(Deramecourt 2011) 
 
Perivascular space dilatation 
0= Absent 
1= The perivascular space is < the artery diameter in all sections 
2= The perivascular space is ≥ the artery diameter in a minority of sections 
3= The perivascular space is ≥ the artery diameter in the majority of sections 
 
Perivascular haemosiderin leakage 
0= Absent 
1= <3 haemosiderin granule deposits in the perivascular space 
2= 3 to 5 haemosiderin granule deposits in the perivascular space 
3= >5 haemosiderin granule deposits in the perivascular space 
 
Myelin loss (LFB staining) 
0= Dense and homogeneous myelin staining 
1= Mild diffuse or focal myelin pallor 
2= Severe focal/diffuse myelin pallor with vacuolation or tigroid appearance of the white matter 
3= Total focal/diffuse destruction of the myelin, or white matter infarcts 
 
Microinfarcts         
0= absent              
1= present           
 
Large infarcts 
0= absent 
1= present 
 
Microhaemorrhage           
0= absent                        
1= present                        
 
Larger haemorrhage 
0= absent 
1= present  
Please	record	the	iden/ﬁca/on	number	of	the	case	you	are	assessing	and	your	name	at	the	top	of	the	form	
Lacunar infarcts 
0= absent 
1= solitary 
2= 2-4 
3= 5 or more 
Supplementary	VCING	validation	assessment	form	
 
	 	Perivascular	
space	dila>on	
0-3	
	Perivascular	
haemosiderin	leakage	
0-3		
	Myelin	l ss	
0-3	
	Microinfarcts	
0/1	
	Large	
infarcts	
0/1	
	Lacunar	
infarcts	
0-3	
	Microhaemorrhage	
0/1	
	Larger	
haemorrhage	
0/1	
	Comments				
		
Superior	&	
middle	frontal	
gyri	
				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Superior	and	
middle	temporal	
gyri	
				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Anterior	
Hippocampus	&	
entorhinal	cortex	
				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Posterior	
hippocampus	 				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Occipital	cortex	
including	
Calcarine	cortex	
(BA17	&	18)	
				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Inferior	parietal	
lobule	
				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Frontal	white	
maJer	
				score							 							score				 					score				 									score								 score				 					score				 					score				 					score				
Caudate	nucleus	 				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Globus	pallidus	 				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Internal	capsule	 				score							 							score				 					score									 					score				 	score								 							score				 					score				 					score				
Putamen	 				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Thalamus	 				score							 							score				 						 					score				 	score								 							score				 					score				 					score				
Occipital	white	
maJer	
				score							 							score				 	score			 					score				 	score								 							score				 					score				 					score				
Case	ID:	 Assessor:	
Supplementary Fig. 1:  Topics covered in each round of the Delphi survey.	
 
Round	1	(R1)	 • Present	literature	review	of	previously	published	protocols.	Survey	familiarity,	use	and	critique.	• Agree	important	issues	to	be	resolved	in	order	to	obtain	successful	consensus.	
Round	2	(R2)	
• Select	papers	upon	which	to	base	discussions	and	agree	modiCications	to	previous	protocols	that	would	improve	the	usefulness.		• What	considerations	taken	into	account	when	choosing	which	protocol	to	use.	• Surveyed	level	of	agreement	with	suggested	most	important	issues	from	R1.	• Prioritise	the	immediate	and	long	term	objectives	of	VCING.	
Round	3	(R3)	
• Discuss	deCinitions	of	vascular	brain	lesions.	• Microinfarcts	and	microhaemorrhages	-	differentiate	or	be	co-designated	as	microvascular	lesions?	• Initiate	discussion	of	sampling	procedures	and	which	vessel	and	tissue	pathology	to	assess.	
Round	4	(R4)	
• Feedback	R3	-	discuss	distinction	between	arteriosclerosis	and	arteriolosclerosis.	• Finalise	separate	designation	of	microinfarcts	and	microhaemorrhages.	• Feedback	R3	-	discuss	sampling	procedures	for	amyloid.	• Feedback	R3	brain	regions	to	be	sampled	-	discuss	in	relation	to	cerebral	white	matter.	• Initiate	assessing	and	quantifying	vessel	wall	pathology	:	atheroma	of	circle	of	Willis,	arteriolosclerosis,	CAA.	• Initiate	assessing	and	quantifying	tissue	damage	caused	by/associated	with	vessel	disease.	
Round	5	(R5)	
• Survey	preferred	deCinitions	for	arteriosclerosis,	atherosclerosis	and	atheroma.	• Feedback	R4	-	agree	on	Chemicon	Clone	4G8	for	labelling	Aβ.	• Feedback	R4:	discuss	scoring	arteriolosclerosis	and	arteriosclerosis	and	complications	of	arteriolosclerosis	(Cibrinoid	necrosis,	microaneurysms).	• Feedback	R4:	preferences	for	scoring	of	capillary	and	arteriolar	CAA.	• Feedback	R4:	recommend	Deramecourt	scheme	–	adaptation?	
Round	6	(R6)	
• Participants	to	propose	deCinition	of	microhaemorrhage;	larger	haemorrhage;	white	matter	pallor.	• Discuss	criteria	for	diagnosing	white	matter	rarefaction.	• Feedback	R5:	reCine	the	deCinition	of	arteriolosclerosis	and	Cinalise	deCinition	of	atherosclerosis.	• Survey	if	Perls'	stain	recommended	for	haemosiderin	granules.	• Finalise	how	to	score	arteriosclerosis	and	arteriolosclerosis;	Cibrinoid	necrosis	and	microaneuryms.	• Finalise	scoring	schemes	for	CAA.	• Initiate	discussion	on	how	to	incorporate	tissue	pathologies	into	the	Deramecourt	scheme.	
Round	7	(R7)	
• Finalise	deCinition	of	microhaemorrhage	and	larger	haemorrhage.	• Adaptation	of	deCinition	of	arteriosclerosis?		• Finalise	how	tissue	pathologies	are	incorporated	in	the	Deramecourt	scoring	scheme.	
Round	8	(R8)	 • Summary	results	from	R1-7	presented	and	questions	to	conCirm	support,	or	highlight	areas	to	be	addressed.	
Round	9	(R9)	
• Amendments	on	which	sections	to	stain.		• CAA	clariCication	–	all	4	lobes	and	hippocampus.	• Survey	how	best	to	validate	VCING.	
